Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on SalesTimes Interest Earned

KalVista Pharmaceuticals (KALV) EBIT Margin (2016 - 2020)

KalVista Pharmaceuticals' EBIT Margin history spans 7 years, with the latest figure at 234.21% for Q2 2020.

  • For Q2 2020, EBIT Margin rose 15062.0% year-over-year to 234.21%; the TTM value through Jan 2021 reached 1277.12%, down 91385.0%, while the annual FY2025 figure was 3249.7%, 353059.0% up from the prior year.
  • EBIT Margin for Q2 2020 was 234.21% at KalVista Pharmaceuticals, up from 806.85% in the prior quarter.
  • Across five years, EBIT Margin topped out at 61.34% in Q2 2018 and bottomed at 5680.21% in Q3 2017.
  • The 5-year median for EBIT Margin is 334.35% (2019), against an average of 1196.47%.
  • The largest annual shift saw EBIT Margin tumbled -515508bps in 2017 before it soared 549169bps in 2018.
  • A 5-year view of EBIT Margin shows it stood at 2043.15% in 2016, then skyrocketed by 74bps to 526.8% in 2017, then skyrocketed by 83bps to 87.5% in 2018, then tumbled by -171bps to 236.96% in 2019, then rose by 1bps to 234.21% in 2020.
  • Per Business Quant, the three most recent readings for KALV's EBIT Margin are 234.21% (Q2 2020), 806.85% (Q1 2020), and 236.96% (Q4 2019).